Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction.
Burke
G W
GW
University of Miami School of Medicine, Department of Surgery, Florida 33136, USA.
Ciancio
G
G
Alejandro
R
R
Roth
D
D
Ricordi
C
C
Tzakis
A
A
Miller
J
J
D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology* / Q000379:methods; D011183:Postoperative Complications / Q000453:epidemiology; D011292:Premedication; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D008776:Methylprednisolone Hemisuccinate; D009173:Mycophenolic Acid; D016559:Tacrolimus